Please login to the form below

Not currently logged in
Email:
Password:

PD-L1/ PD-1 inhibitor

This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Merck shares positive late-stage results for Welireg in advanced kidney cancer

RCC that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapies. ... Patients with advanced RCC face low survival rates, and for those whose cancer progresses following

Latest news

More from news
Approximately 1 fully matching, plus 64 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Avalere Health

Avalere Health is a leading global commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Working from advisory to...

Latest intelligence

Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...